DEADLINE ALERT for ORCL, PSFE, INO, KD: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1][2]. Oracle Corporation (NYSE: ORCL) - Class period is from June 12, 2025, to December 16, 2025, with a lead plaintiff deadline of April 6, 2026 [2]. - Allegations include misleading statements regarding Oracle's AI infrastructure strategy, which is expected to lead to significant increases in capital expenditures without corresponding near-term revenue growth [3]. - Concerns raised about increased spending affecting Oracle's debt, credit rating, free cash flow, and project funding capabilities [3]. Paysafe Limited (NYSE: PSFE) - Class period is from March 4, 2025, to November 12, 2025, with a lead plaintiff deadline of April 7, 2026 [4]. - Allegations include significant exposure to a high-risk client in its e-commerce business, leading to understated credit loss reserves and write-offs [4]. - Issues with higher risk Merchant Category Codes are said to complicate client services, potentially impacting revenue growth and financial guidance for fiscal year 2025 [4]. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) - Class period is from October 10, 2023, to December 26, 2025, with a lead plaintiff deadline of April 7, 2026 [5]. - Allegations include deficiencies in manufacturing for Inovio's CELLECTRA device, affecting the submission of the INO-3107 Biologics License Application (BLA) to the FDA [5]. - Concerns about overstated regulatory and commercial prospects for INO-3107 due to insufficient information for FDA approval [5]. Kyndryl Holdings, Inc. (NYSE: KD) - Class period is from August 7, 2024, to February 9, 2026, with a lead plaintiff deadline of April 13, 2026 [6]. - Allegations include materially misstated financial statements and inadequate internal controls, which may delay the filing of the Quarterly Report for the quarter ended December 31, 2025 [6]. - Positive statements about Kyndryl's business and operations are claimed to be materially misleading [6].